



1617 / Ifed

Whereby I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on August 28, 2006

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI-350C1
Serial No. 10/660,202

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §§1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 10/378,956, filed March 3, 2003;
U.S. Serial No. 10/637,829, filed August 8, 2003;
U.S. Serial No. 10/295,995, filed November 18, 2002, now U.S. Patent No. 6,699,840;
U.S. Serial No. 10/232,589, filed September 3, 2002, now U.S. Patent No. 6,559,293;
U.S. Serial No. 10/449,307, filed March 30, 2003, now U.S. Patent No. 7,078,526; and
U.S. Serial No. 10/601,092, filed June 20, 2003.


The subject application, Serial No. 10/660,202, claims the benefit under 35 USC §120 of the filing date of patent applications referred to above. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the application referred to above, as

well as any references cited during the prosecution thereof, be made of record in the 10/660,202 application. As copies of the references made of record in the applications referred to above, and cited on the attached form PTO/SB/08, can be found in the casefiles referred to above, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	1	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2,711,411	06-21-1955	Holbert, <i>et al.</i>	All
	U2	US-4,198,507	04-15-1980	Barry, <i>et al.</i>	All
	U3	US-4,368,197	01-11-1983	Shefter, <i>et al.</i>	All
	U4	US-4,994,604	02-19-1991	Tung, <i>et al.</i>	All
	U5	US-5,177,262	01-15-1993	Taylor, <i>et al.</i>	All
	U6	US-5,332,834	07-26-1994	Bhattacharya, <i>et al.</i>	All
	U7	US-5,338,644	08-16-1994	Taylor, <i>et al.</i>	All
	U8	US-5,380,867	01-10-1995	Bhattacharya, <i>et al.</i>	All
	U9	US-5,412,094	05-02-1995	Amos, <i>et al.</i>	All
	U10	US-5,523,090	06-04-1996	Znaiden, <i>et al.</i>	All
	U11	US-5,614,342	03-25-1997	Molaire, <i>et al.</i>	All
	U12	US-5,998,413	12-07-1999	Heeres, <i>et al.</i>	All
	U13	US-6,001,996	12-14-1999	Amos, <i>et al.</i>	All
	U14	US-6,268,385	07-31-2001	Whittle, <i>et al.</i>	All
	U15	US-6,570,036	05-27-2003	Reuter	All
	U16	US-2003/0162226	08-28-2003	Cima, <i>et al.</i>	All
	U17	US-2003/0166581	09-04-2003	Almarsson, <i>et al.</i>	All
	U18	US-2003/0224006	12-04-2003	Zaworotko, <i>et al.</i>	All
	U19	US-2004/0019211	01-29-2004	Remenar, <i>et al.</i>	All
	U20	US-2004/0106052	06-03-2004	Molaire	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	2	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U21	US-2004/0106053	06-03-2004	Molaire, <i>et al.</i>	All
	U22	US-2004/0106055	06-03-2004	Molaire, <i>et al.</i>	All
	U23	US-2004/0171062	09-02-2004	Hirth, <i>et al.</i>	All
	U24	US-2004/0176335	09-09-2004	Childs	All
	U25	US-2005/0070551	03-31-1995	Remenar, <i>et al.</i>	All
	U26	US-2005/0181041	08-18-2005	Goldman	All
	U27	US-2005/0169982	08-04-2005	Almarsson, <i>et al.</i>	All
	U28	US-2005/0252649	11-17-2005	Chiu, <i>et al.</i>	All
	U29	US-2005/0256127	11-17-2005	Ku, <i>et al.</i>	All
	U30	US-6,559,293	05-06-2003	Almarsson, <i>et al.</i>	All
	U31	US-6,699,840	03-02-2004	Almarsson, <i>et al.</i>	All
	U32	US-2004-0053853	03-18-2004	Almarsson, <i>et al.</i>	All
	U33	US-2005/0070551 A1	03-31-2005	Remenar, <i>et al.</i>	All
	U34	US-2003/00224006	12-04-2003	Zaworotko <i>et al.</i>	All
	U35	US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
	U36	US-3,598,123	08-10-1971	Zaffaroni	All
	U37	US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
	U38	US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
	U39	US-4,008,719	02-22-1977	Theeuwes <i>et al.</i>	All
	U40	US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
	U41	US-4,764,604	08-16-1988	Muller	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Art Unit	1617
Examiner Name	Leonard Williams
Attorney Docket Number	TPI-350C1

Sheet	3	of	36
-------	---	----	----

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U42	US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
	U43	US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
	U44	US-5,059,595	10-22-1991	Le Grazie	All
	U45	US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
	U46	US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All
	U47	US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
	U48	US-5,414,997	05-16-1995	Tailer	All
	U49	US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
	U50	US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
	U51	US-5,633,015	05-27-1997	Gilis <i>et al.</i>	All
	U52	US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
	U53	US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
	U54	US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
	U55	US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
	U56	US-5,733,566	03-31-1998	Lewis	All
	U57	US-2003/0096014	05-22-2003	Sherman	All
	U58	US-4,513,006	04-23-1995	Maryanoff <i>et al.</i>	All
	U59	US-6,191,117	02-20-2001	Kozachuk	All
	U60	US-6,201,010	03-13-2001	Cottrell	All
	U61	US-5,753,693	05-19-1998	Shank	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

36

Application Number

10/660,202

Filing Date

September 11, 2003

First Named Inventor

Örn Almarsson

Art Unit

1617

Examiner Name

Leonard Williams

Attorney Docket Number

TPI-350C1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U62	US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
	U63	US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
	U64	US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
	U65	US-5,760,007	06-02-1999	Shank <i>et al.</i>	All
	U66	US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
	U67	US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
	U68	US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
	U69	US-6,071,537	06-06-2000	Shank	All
	U70	US-6,503,884	01-07-2003	Ehrenberg <i>et al.</i>	All
	U71	US-2003/0069190	04-10-2003	Abdel-Magid <i>et al.</i>	All
	U72	US-2002/0042446	04-11-2002	Dewey <i>et al.</i>	All
	U73	US-2002/0037925	03-28-2002	Dewey <i>et al.</i>	All
	U74	US-2003/0072802	04-17-2003	Cutler	All
	U75	US-6,488,962	12-03-2002	Berner <i>et al.</i>	All
	U76	US- 7,078,526	07-18-2006	Remenar <i>et al.</i>	All
	U77	US-6,294,192	9-25-2001	Patel <i>et al.</i>	All
	U78	US-5,466,823	11-14-1995	Talley <i>et al.</i>	All
	U79	US-4,008,321	02-15-1977	Kamishita <i>et al.</i>	All
	U80	US-4,853,379	08-01-1989	Shroot <i>et al.</i>	All
	U81	US-5,641,512	06-24-1997	Cimiluca	All

Examiner
Signature

/Renee Claytor/

Date

Considered

11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	5	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U82	US-6,420,394 B1	07-16-2002	Supersaxo	All
	U83	US-2003/0224006 A1	12-04-2003	Zaworotko <i>et al.</i>	All
	U84	US-			
	U85	US-			
	U86	US-			
	U87	US-			
	U88	US-			
	U89	US-			
	U90	US-			
	U91	US-			
	U92	US-			
	U93	US-			
	U94	US-			
	U95	US-			
	U96	US-			
	U97	US-			
	U98	US-			
	U99	US-			
	U100	US-			
	U101	US-			

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	6	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	EP 413528 B1	11-15-1995	Yu, R. <i>et al.</i>	All	
	F2	EP 1364649 A1	11-26-2003	Cilag AG	All	
	F3	WO 94/16733 A1	08-04-1994	Chiesi Farmaceutici S.P.A.	All	
	F4	WO 96/07331 A1	03-14-1996	Xyrofin Oy	All	
	F5	WO 98/57967 A1	12-23-1998	Dong-A Pharmaceutical Co., Ltd.	All	
	F6	WO 2000/53283 A1	09-14-2000	Reuter Chemische Apparatebau KG	All	
	F7	WO 2001/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical, Inc.	All	
	F8	JP 54-16494	02-07-1979	Yamanouchi Pharmaceutical Co., Ltd.	All	X
	F9	WO 00/50020 A2	08-31-2000	University of Cincinnati	All	
	F10	FR 769,586	06-11-1934	Chemische Fabrik von Heyden	All	X
	F11	IT 01303251	11-06-2000	Industriale Chimica, S.R.L.	All	X
	F12	WO 2001/97853 A1	12-27-2001	Biochemie Gesellschaft MBH	All	
	F13	EP 0310122 B1	04-05-1989	Kaken Pharma	All	
	F14	WO 2002/062318 A2	08-15-2002	DSM N.V.	All	
	F15	EP 0283992 B1	09-16-1992	Janssen Pharma	All	
	F16	WO 2003/101392 A2	12-11-2003	Transform Pharmaceuticals, Inc.	All	
	F17	WO 2004/054571 A1	07-01-2004	Cilag AG	All	
	F18	WO 2004/078161 A1 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All	
	F19	WO 2004/078163 A2 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	7	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
	F20	WO	2004/089313 A2	10-21-2004	Transform Pharmaceuticals, Inc.	All
	F21	WO	2005/023198 A2 (CD-ROM)	03-17-2005	Transform Pharmaceuticals, Inc.	All
	F22	WO	2005/037424 A1	04-28-2005	Salvias AG	All
	F23	WO	2005/055983 A2	06-23-2005	Medcrystalforms, LCC	All
	F24	WO	2005/060968 A1 (CD-ROM)	07-07-2005	Sepracor, Inc.	All
	F25	WO	2005/089375 A2 (CD-ROM)	09-29-2005	S.S.C.I., Inc.	All
	F26	WO	2005/094804 A1	10-13-2005	The Regents of the University of Michigan	All
	F27	WO	2006/024930 A1	03-09-2006	Pharmacia and Upjohn Co., LCC	All
	F28	WO	03/070738 A2	08-28-2003	Transform Pharmaceuticals, Inc.	All
	F29	WO	03/074474 A2	09-12-2003	Univ. South Fl	All
	F30	WO	95/17407 A1	06-29-1995	Schering Corp	All
	F31	WO	00/07583 A2	02-17-2000	Brookhaven Science Associates	All
	F32	WO	00/72841 A1	12-07-2000	Berlant, Jeffrey	All
	F33	WO	03 033462 A2	04-23-2003	Regents of Univ. Mich.	All
	F34	WO	01 51919 A2	07-19-2001	Transform Pharm. Inc.	All
	F35	WO	01 42222 A1	06-14-2001	Pharmacia Corp.	All
	F36	WO	95/23596 A1	09-08-1995	The Boots Co.	All
	F37	WO	00/32189 A1	06-08-2000	G. D. Searle & Co.	All
	F38	WO	01/41760 A3	06-14-2001	Pharmacia Corporation	All
	F39	WO	01/78724 A1	10/25/2001	Pharmacia Corporation	All
	F40	WO	01/91750 A1	12/06/2001	Pharmacia Corporation	All
	F41	WO	02/00627 A1	01/03/2002	Fako Ilacilari A.S.	All
	F42	IN	182620	12-24-1994	Bajaj et al.	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

36

Application Number

10/660,202

Filing Date

September 11, 2003

First Named Inventor

Örn Almarsson

Group Art Unit

1617

Examiner Name

Leonard Williams

Attorney Docket Number

TPI-350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AAKERÖY, C. <i>et al.</i> "Crystal engineering of hydrogen-bonded assemblies- a progress report" <i>Aust. J. Chem.</i> , 2001, pp. 409-421, Vol. 54.	
	R2	BINGHAM, A. <i>et al.</i> "Over one hundred solvates of sulfathiazole" <i>Chem. Commun.</i> , 2001, pp. 603-604.	
	R3	BYRIEL, K., <i>et al.</i> "Molecular cocrystals of carboxylic acids. IX Carboxylic acid interactions with organic heterocyclic bases. The crystal structures of the adducts of (2,4-dichlorophenoxy) acetic acid with 3-hydroxypyridine, 2,4,6-trinitrobenzoic acid with 2-aminopyrimidine, and 4-nitrobenzoic acid with 3-amino-1,2,4-triazole" <i>Aust. J. Chem.</i> , 1992, pp. 969-981, Vol. 45, No. 6.	
	R4	SALMON, J. <i>et al.</i> "Supramolecular chemistry of boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R5	URBINA, J. <i>et al.</i> "Supramolecular design of inorganic/organic networks using flexible ligands with self-complementary hydrogen bonds (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	

Examiner
Signature

/Benee Claytor/

Date

Considered

11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	9	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R6	SMITH, D. <i>et al.</i> "Structure confirmation by single crystal X-ray diffraction of a series of new schiff bases and theoretical computations on 3-(N-2- α , α , α -trifluorotoluidylidene amino) tetrahydrothiophene-1, 1-dioxide (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	
	R7	DESIRAJU, G. "Supramolecular synthons in crystal engineering- A new organic synthesis" <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, pp. 2311-2327, Vol. 34.	
	R8	FRITCHIE, C. <i>et al.</i> "The configuration of phenothiazine in various molecular complexes" <i>Chem. Commun.</i> , 1968, pp. 833-834.	
	R9	HUANG, C.-M. <i>et al.</i> "Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid" <i>J. Chem. Soc. Perkins Trans. 2: Physical Organic Chemistry</i> , 1973, pp. 503-508, Vol. 5.	
	R10	JACKISCH, M. <i>et al.</i> "Structures of three related biphenyl compounds: 4,4'-biphenyldiol, 3, 3',5,5'-tetra- <i>tert</i> -butyl-4,4'-biphenyldiol, and 3,3',5,5'- tetra- <i>tert</i> -butyl-1,1'-bicyclohexa-2,5-dienylidene-4,4'-dione" <i>Acta Cryst.</i> , 1990, pp. 919-922, Vol. C46.	
	R11	KIM, S. <i>et al.</i> "The structure of a crystalline complex containing one phenobarbital molecule and two adenine derivatives" <i>Proc. Natl. Acad. Sci. USA</i> , 1968, pp. 402-408, Vol. 60.	
	R12	KOBAYASHI, H. <i>et al.</i> "Sinusoidal structure of the 1:1 complex of phenothiazine and 7,7,8,8-tetracyanoquinodimethane, PTZ-TCNQ" <i>Acta Cryst.</i> , 1974, pp. 1010-1017, Vol. B30.	
	R13	ERMER, O. <i>et al.</i> "Molecular recognition among alcohols and amines: super-tetrahedral crystal architectures of linear diphenol-diamine complexes and aminophenols" <i>J. Chem. Soc. Perkins Trans. 2</i> , 1994, pp. 925-944.	
	R14	MARTIN, R. <i>et al.</i> "Polyphenal-caffeine complexation" <i>J. Chem. Soc., Chem. Commun.</i> , 1986, pp. 105-106.	
	R15	LEHN, J.-M. <i>et al.</i> "Molecular recognition directed self-assembly of ordered supramolecular strands by cocrystallization of complementary molecular components" <i>Chem. Soc., Chem. Commun.</i> , 1990, pp. 479-481.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

10

of

36

Application Number

10/660,202

Filing Date

September 11, 2003

First Named Inventor

Örn Almarsson

Group Art Unit

1617

Examiner Name

Leonard Williams

Attorney Docket Number

TPI-350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R16	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XV Preparation and characterization of heterocyclic base adducts with a series of carboxylic acids, and the crystal structures of the adducts of 2-aminopyrimidine with 2,6-dihydroxybenzoic acid, 4-aminobenzoic acid, phenoxyacetic acid, (2,4-dichlorophenoxy) acetic acid, (3,4-dichlorophenoxy)-acetic acid and salicylic acid, and 2-aminopyrimidine with 2,6-dihydroxybenzoic acid" <i>Aust. J. Chem.</i> , 1994, pp. 1097-1115, Vol. 47.	
	R17	MCINTOSH, J. <i>et al.</i> "Chemotherapeutic drugs in anaerobic infections of wounds" <i>The Lancet</i> , June 26, 1943, pp. 793-795.	
	R18	MCINTOSH, J. <i>et al.</i> "Zinc peroxide, proflavine and penicillin in experimental <i>cl. welchii</i> infections" <i>The Lancet</i> , December 26, 1942, pp. 750-752.	
	R19	SMITH, G. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXI The role of secondary group interactions in adduct formation between 2-aminopyrimidine and substituted benzoic acids: the crystal structures of the adducts with <i>o</i> -phthalic acid, <i>o</i> -nitrobenzoic acid, <i>o</i> -aminobenzoic acid and <i>m</i> -aminobenzoic acid" <i>Aust. J. Chem.</i> , 1995, pp. 1151-1166, Vol. 48.	
	R20	WEISSBUCH, I. <i>et al.</i> "Crystal morphology control with tailor-made additives; a stereochemical approach" <i>Advances in Crystal Growth Research</i> , 2001, pp. 381-400.	
	R21	MCAHON, J. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. 3 ¹ . Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals" <i>Z. Kristallogr.</i> , 2005, pp. 340-350, Vol. 220.	
	R22	MEEJOO, S. <i>et al.</i> "The interplay of aryl-perfluoroaryl stacking interactions and interstack hydrogen bonding in controlling the structure of a molecular cocrystal" <i>Chemphyschem</i> , 2003, pp. 766-769, Vol. 4.	
	R23	MIRMEHRABI, M. <i>et al.</i> "Improving the filterability and solid density of ranitidine hydrochloride form 1" <i>Journal of Pharmaceutical Sciences</i> , July 2004, pp. 1692-1700, Vol. 93, No. 7.	
	R24	MORRIS, K. <i>et al.</i> "Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 91-114, Vol. 48.	

Examiner
Signature

/Renee Claytor/

Date

Considered

11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	11	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R25	NAKANISHI, I. <i>et al.</i> "X-ray structural studies on two forms of β -cyclodextrin barbitol complexes" <i>Journal of Inclusion Phenomena</i> , 1984, pp. 689-699, Vol. 2.		
	R26	NAKAO, S. <i>et al.</i> "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital" <i>Acta Cryst.</i> , 1977, pp. 1373-1378, Vol. B33.		
	R27	NATARAJAN, S. <i>et al.</i> "Reinvestigation of the crystal structure of diglycine hydrochloride" <i>Zeitschrift für Kristallographie</i> , 1992, pp. 265-270, Vol. 198.		
	R28	OLENIK, B. <i>et al.</i> "Cooperative and anticooperative effects in the cocrystals of mono- and diazanaphthalenes with <i>meso</i> -1, 2-diphenyl-1,2-ethanediol" <i>Crystal Growth & Design</i> , 2003, pp. 175-181, Vol. 3, No. 2.		
	R29	OLENIK, B. <i>et al.</i> "Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes" <i>Crystal Growth & Design</i> , 2003, pp. 183-188, Vol. 3, No. 2.		
	R30	GROTH, P. " <i>d</i> -Glucose-sodium chloride-monohydrate (glucose-sodium chloride) = $2C_6H_{12}O_6 \cdot NaCl \cdot H_2O$ " <i>Chemische Kristallographie</i> , 1910, pp. 438-439.	X	
	R31	OSWALD, I. <i>et al.</i> "Rationalisation of co-crystal formation through knowledge-mining" <i>Crystallography Reviews</i> , 2004, pp. 57-66, Vol. 10, No. 1.		
	R32	OUYANG, X. <i>et al.</i> "Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer" <i>J. Am. Chem. Soc.</i> , 2003, pp. 12400-12401, Vol. 125.		
	R33	PATEL, U. <i>et al.</i> "Structure of the 1:1 complex between 4-amino- <i>N</i> -(4,6-dimethyl-2-pyrimidinyl)- benzenesulfonamide (sulfadimidine) and 2-hydroxybenzoic acid (salicylic acid)" <i>Acta Cryst.</i> , 1988, pp. 1264-1267, Vol. C44.		
	R34	REDDY, L. <i>et al.</i> "Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides" <i>Crystal Growth & Design</i> , 2004, pp. 89-94, Vol. 4., No. 1.		
	R35	REMENAR, J. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.		

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	12	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R36	SCHMIDT, G. "Photodimerization in the solid state" <i>Pure Appl. Chem.</i> , 1971, pp. 647-678, Vol. 27.	
	R37	SHAN, N. <i>et al.</i> "Co-crystal of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction" <i>Tetrahedron Letters</i> , 2002, pp. 8721-8725, Vol. 43.	
	R38	SHAN, N. <i>et al.</i> "Crystal engineering using 4,4'-bipyridyl with di- and tricarboxylic acids" <i>Crystal Engineering</i> , 2002, pp. 9-24, Vol. 5.	
	R39	SHAN, N. <i>et al.</i> "Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids" <i>Tetrahedron Letters</i> , 2002, pp. 3101-3104, Vol. 43.	
	R40	MCINTOSH, J. <i>et al.</i> "Further observations on the chemotherapy of experimental gas gangrene: flavazole, marfanil, V187 and V335" <i>British Journal of Experimental Pathology</i> , 1946, pp. 46-54, Vol. 27.	
	R41	SHAVIV, R. <i>et al.</i> "Magnetochemistry of the tetrahaloferrate (III) ions 6. Crystal structure and magnetic ordering in [(pyH) ₃ Cl] [FeCl ₄] ₂ " <i>Inorganica Chimica Acta</i> , 1992, pp. 613-621, Vol. 198-200.	
	R42	SHEFTER, E. "Structural studies on complexes IV: Crystal structure of a 1:1 5-chlorosalicylic acid and theophylline complex" <i>Journal of Pharmaceutical Sciences</i> , 1969, pp. 710-714, Vol. 58.	
	R43	SHIMIZU, N. <i>et al.</i> "Structure of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine-5,5-diethylbarbituric acid (1:1)" <i>Acta Cryst.</i> , 1982, pp. 2309- 2311, Vol. B38.	
	R44	SINGH, N. B. <i>et al.</i> "Solid state reaction between 8-hydroxyquinoline and <i>p</i> -nitrobenzoic acid" <i>Indian Journal of Chemistry</i> , May 1988, pp. 429-432, Vol. 37B.	
	R45	SMITH, G. <i>et al.</i> "The 1:1 adduct of 4-aminobenzoic acid with 4-aminobenzonitrile" <i>Acta Cryst.</i> , 2000, pp. 1155-1156, Vol. C56.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	13	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R46	STEINER, T. "Donor and acceptor strengths in C-H...O hydrogen bonds quantified from crystallographic data of small solvent molecules" <i>New. J. Chem.</i> , 1998, pp. 1099-1103.	
	R47	STOREY, R. et al. "Automation of solid form screening procedures in the pharmaceutical industry- how to avoid the bottlenecks" <i>Crystallography Reviews</i> , 2004, pp. 45-56, Vol. 10, No. 1.	
	R48	SZAFRAN, M. et al. "Molecular structures and hydrogen bonding in the 1:1 and 1:2 complexes of pyridine betaine with 2,6-dichloro-4-nitrophenol; an example of strongly coupled hydrogen bonds, O-H...O=C-O-H...O-" <i>Journal of Molecular Structure</i> , 1997, pp. 145-160, Vol. 416.	
	R49	TAKEUCHI, M. et al. "Synchrotron radiation SAXS/WAXS study of polymorph-dependent phase behavior of binary mixtures of saturated monoacid triacylglycerols" <i>Crystal Growth & Design</i> , 2003, pp. 369-374, Vol. 3, No. 3.	
	R50	TANG, C. P. et al. "Reaction pathways in crystalline host-guest inclusion complexes: rotation by a net 180° of the acetyl group on photoaddition of guest- acetophenone and - <i>m</i> -Chloroacetophenone to the atom C5 of host deoxycholic acid" <i>J. Am. Chem. Soc.</i> , 1985, pp. 4058-4070, Vol. 107.	
	R51	TAYLOR, R. et al. "Rules governing the crystal packing of mono- and dialcohols" <i>Acta Crystallographica Section B, Structural Science</i> , 2001, pp. 815-827, Vol. B57.	
	R52	THALLAPALLY, P. et al. "Polymorphism of 1,3,5-trinitrobenzene induced by a trisindane additive" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 1149-1155, Vol. 43.	
	R53	TIMMERMAN, P. et al. "Noncovalent Assembly of functional groups on calix[4]arene molecular boxes" <i>Chem. Eur. J.</i> , 1997, pp. 1823-1832, Vol. 3., No. 11.	
	R54	SHAN, N. et al. "Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics" <i>Chem. Commun.</i> , 2002, pp. 2372-2373.	
	R55	CAIRA, M. et al. "X-ray structure and thermal analysis of a 1:1 complex between (S)-naproxen and heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1995, pp. 277-290, Vol. 20.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	14	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R56	TRASK, A. <i>et al.</i> "Crystal engineering of organic cocrystals by the solid-state grinding approach" <i>Top Curr. Chem.</i> , 2005, pp. 41-70, Vol. 254.		
	R57	TRASK, A. <i>et al.</i> "Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration" <i>Crystal Growth & Design</i> , 2005, pp. 1013-1021, Vol. 5, No. 3.		
	R58	TRASK, A. <i>et al.</i> "Solvent-drop grinding: green polymorph control of cocrystallisation" <i>Chem. Commun.</i> , 2004, pp. 890-891 in addition to supplemental materials.		
	R59	TROWBRIDGE, L. <i>et al.</i> "Composites for nonlinear optics: Crystal growth and polymorphism" <i>University of Sussex, Falmer Brighton UK, School of Chemistry and Molecular Sciences</i> , pp. 272.1994		
	R60	UNO, T. <i>et al.</i> "Structure of 5,5-diphenylhydantoin-1- (4-bromophenyl)-4-dimethylamino-2,3-dimethyl-3-pyrazolin-5-one (1:1)" <i>Acta Cryst.</i> , 1980, pp. 2794-2796, Vol. B36.		
	R61	VAN ROEY, P. <i>et al.</i> "Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B" <i>J. Enzyme Inhibition</i> , 1991, pp. 119-132, Vol. 5.		
	R62	VAN ROEY, P. <i>et al.</i> "Structure of <i>cis</i> -1-[[4-(1-imidazolylmethyl) cyclohexyl] methyl] imidazole- succinic acid complex" <i>Acta Cryst.</i> , 1991, pp. 1015-1018, Vol. C47.		
	R63	VISHWESHWAR, P. <i>et al.</i> "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients" <i>Chem. Commun.</i> , 2005, pp. 4601-4603.		
	R64	VISHWESHWAR, P. <i>et al.</i> "Recurrence of carboxylic acid- pyridine supramolecular synthon in the crystal structures of some pyrazinecarboxylic acids" <i>J. Org. Chem.</i> , 2002, pp. 556-565, Vol. 67.		
	R65	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid" <i>Chem. Commun.</i> , 2002, pp. 1830-1831.		
	R66	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons in phenol-isonicotinamide adducts" <i>Cryst. Eng. Comm.</i> 2003, pp. 164-168, Vol. 5, No. 31.		

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

15

of

36

Application Number

10/660,202

Filing Date

September 11, 2003

First Named Inventor

Örn Almarsson

Group Art Unit

1617

Examiner Name

Leonard Williams

Attorney Docket Number

TPI-350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R67	VOET, D. <i>et al.</i> "The crystal and molecular structure of the intermolecular complex 9-ethyladenine-5, 5-diethylbarbituric acid" <i>Journal of the American Chemical Society</i> , November 15, 1972, pp. 8213-8222, Vol. 94, No. 23.	
	R68	VOET, D. <i>et al.</i> "The structure of an intermolecular complex between cytosine and 5-fluorouracil" <i>Journal of the American Chemical Society</i> , May 21, 1969, pp. 3069-3075, Vol. 91, No. 11.	
	R69	STEZOWSKI, J. J. <i>et al.</i> "Characterization of a 1:1 complex of an unusual structure in the phenothiazine/phenazine binary phase diagram" <i>Zeitschrift fur Kristallographie in International Journal for Structural, Physical, Chemical Aspects of Crystalline Materials</i> , 1983, pp. 213-215, Vol. 162, No. 1-4.	X
	R70	WANG, A. <i>et al.</i> "Crystal structure of 1:1 complex of barbitol with 1-methylimidazole" <i>Journal of Pharmaceutical Sciences</i> , March 1979, pp. 361-363, Vol. 68, No. 3.	
	R71	ALBEROLA, S. <i>et al.</i> "Crystalline and Molecular Structure of Sulfanilimide-Antipyrine" <i>Acta Cryst.</i> , 1977, pp. 3337-3341, Vol. B33.	X
	R72	WOOD, R. A. <i>et al.</i> "2,5-O-methylene-D-mannitol sodium-chloride, C ₇ H ₁₄ O ₆ . NaCl" <i>Cryst. Struct. Comm.</i> , 1976, 207-210, Vol. 5.	
	R73	XU, J. <i>et al.</i> "Effect of composition distribution on miscibility and co-crystallization phenomena in the blends of low density polyethylene with conventional and metallocene-based ethylene-butene copolymers" <i>Polymer</i> , 2001, pp. 3867-3874, Vol. 42.	
	R74	YOO, J. <i>et al.</i> "Cocrystallization of a dinuclear platinum complex as a monomer and a one-dimensional polymer" <i>Polyhedron</i> , 2002, pp. 715-719, Vol. 21.	
	R75	ZAITU, S. <i>et al.</i> "A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate" <i>Acta Cryst.</i> , 1995, pp. 1857-1859, Vol. C51.	
	R76	ZAMAN, M. B. <i>et al.</i> "Linear hydrogen-bonded molecular tapes in the cocrystals of squaric acid with 4,4'-dipyridylacetylene and 1,2-bis(4-pyridyl) ethylene" <i>Acta Cryst.</i> , 2001, pp. 621-624, Vol. C57.	
	R77	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: hydrogen-bonded molecular "tapes" ¹ " <i>J. Am. Chem. Soc.</i> , 1990, pp. 9025-9026, Vol. 112.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	16	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R78	ZERKOWSKI, J. <i>et al.</i> "Investigations into the robustness of secondary and tertiary architecture of hydrogen-bonded crystalline tapes" <i>Chem. Mater.</i> , 1994, pp. 1250-1257, Vol. 6.	
	R79	ZERKOWSKI, J. <i>et al.</i> "New varieties of crystalline architecture produced by small changes in molecular structure in tape complexes of melamines and barbiturates" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4305-4315, Vol. 116.	
	R80	ZERKOWSKI, J. <i>et al.</i> "Polymorphic packing arrangements in a class of engineered organic crystals" <i>Chem. Mater.</i> , 1997, pp. 1933-1941, Vol. 9.	
	R81	ZERKOWSKI, J. <i>et al.</i> "Solid-state structures of "Rosette" and "Crinkled Tape" motifs derived from the cyanuric acid-melamine lattice" <i>J. Am. Chem. Soc.</i> , 1992, pp. 5473-5475, Vol. 114.	
	R82	ZHANG, R. <i>et al.</i> "Atmospheric new particle formation enhanced by organic acids" <i>Science</i> , June 4, 2004, pp. 1487-1490 with additional supporting online material, Vol. 304.	
	R83	ZHU, H. <i>et al.</i> "Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. theophylline" <i>International Journal of Pharmaceutics</i> , 1996, pp. 151-160, Vol. 135.	
	R84	AAKERÖY, C. <i>et al.</i> "Aromatic dicarboxylic acids as building blocks of extended hydrogen-bonded architectures" <i>Supramolecular Chemistry</i> , 1998, pp. 127-135, Vol. 9.	
	R85	AAKERÖY, C. <i>et al.</i> "Assembly of 2-D inorganic/organic lamellar structures through a combination of copper (I) coordination polymers and self-complimentary hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 2000, pp. 3869-3872.	
	R86	AAKERÖY, C. <i>et al.</i> "Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure" <i>Crystal Engineering</i> , 1998, pp. 225-241, Vol. 1, No. 3-4.	
	R87	AAKERÖY, C. <i>et al.</i> "The C-H...C1 hydrogen bond: does it exist?" <i>New J. Chem.</i> , 1999, pp. 145-152.	
	R88	AAKERÖY, C. <i>et al.</i> "Crystal engineering of ionic solids" <i>Modular Chemistry</i> (ed. by Michl, J.), 1997, pp. 153-162, Kluwer Academic Publishers, The Netherlands.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	17	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R89	AAKERÖY, C. <i>et al.</i> "Crystal engineering: strategies and architectures" <i>Acta Cryst.</i> , 1997, pp. 569-586, Vol. B53.	
	R90	AAKERÖY, C. <i>et al.</i> "Crystal engineering using intermolecular hydrogen-bonded connectors and classic coordination chemistry" <i>Transactions ACA</i> , 1998, pp. 97-103, Vol. 33.	
	R91	AAKERÖY, C. <i>et al.</i> "The crystal structure of the molecular cocrystal L-malic acid L-tartaric acid (1/1)" <i>Supramolecular Chemistry</i> , 1996, pp. 153-156, Vol. 7.	
	R92	AAKERÖY, C. <i>et al.</i> "Deliberate combination of coordination polymers and hydrogen bonds in a supramolecular design strategy for inorganic/organic hybrid networks" <i>Chem. Commun.</i> , 2000, pp. 935-936.	
	R93	AAKERÖY, C. <i>et al.</i> "Di-hydroxy malonic acid as a building block of hydrogen-bonded 3-dimensional architectures" <i>Journal of Chemical Crystallography</i> , 1998, pp. 111-117, Vol. 28, No. 2.	
	R94	AAKERÖY, C. <i>et al.</i> "Do polymorphic compounds make good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility" <i>Crystal Growth & Design</i> , 2003, 159-165, Vol. 3, No. 2.	
	R95	AAKERÖY, C. <i>et al.</i> "Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals" <i>Cryst. Eng. Comm.</i> , 2004, pp. 19-24, Vol. 6, No. 5.	
	R96	AAKERÖY, C. <i>et al.</i> "A high-yielding supramolecular reaction" <i>J. Am. Chem. Soc.</i> , 2002, 14425-14432, Vol. 124.	
	R97	AAKERÖY, C. <i>et al.</i> "The hydrogen bond and crystal engineering" <i>Chemical Society Reviews</i> , 1993, pp. 397-407.	
	R98	AAKERÖY, C. <i>et al.</i> "Hydrogen-bond assisted assembly of organic and organic-inorganic solids" <i>Crystal Engineering: From Molecules and Crystals to Materials</i> , 1999, pp. 89-106, Kluwer Academic Publishers, The Netherlands.	
	R99	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonding in solids" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 303-324, Kluwer Academic Publishers, The Netherlands.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/660,202
			Filing Date	September 11, 2003
			First Named Inventor	Örn Almarsson
			Group Art Unit	1617
			Examiner Name	Leonard Williams
			Attorney Docket Number	TPI-350C1
Sheet	18	of	36	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R100	AAKERÖY, C. <i>et al.</i> "Low-dimensional architectures of silver coordination compounds assembled via amide-amide hydrogen bonds" <i>Crystal Engineering</i> , 1998, pp. 39-49, Vol. 1, No. 1.	
	R101	AAKERÖY, C. <i>et al.</i> "Molecular mechanics and crystal engineering" " <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 69-82, Kluwer Academic Publishers, The Netherlands.	
	R102	AAKERÖY, C. <i>et al.</i> "New building blocks for crystal engineering. Syntheses and crystal structures of oxime-substituted pyridines" <i>Cryst. Eng. Comm.</i> , 2000, pp. 1-6, Vol. 27.	
	R103	AAKERÖY, C. <i>et al.</i> "Novel colorless composite materials for nonlinear optics" <i>Adv. Mater.</i> , 1993, pp. 364-367, Vol. 5, No. 5.	
	R104	AAKERÖY, C. <i>et al.</i> "Organic assemblies of 2-pyridones with dicarboxylic acids" <i>Tetrahedron</i> , 2000, pp. 6693-6699, Vol. 56.	
	R105	AAKERÖY, C. <i>et al.</i> "Pitfalls in the supramolecular assembly of silver(I) coordination compounds" <i>Journal of Molecular Structure</i> , 1999, pp. 91-101, Vol. 474.	
	R106	AAKERÖY, C. <i>et al.</i> "A structural study of 2-amino-5-nitropyridine and 2-amino-3-nitropyridine: intermolecular forces and polymorphism" <i>J. Mater. Chem.</i> , 1998, pp. 1385-1389, Vol. 8, No. 6.	
	R107	AAKERÖY, C. <i>et al.</i> "Supramolecular assembly of low-dimensional silver (I) architectures via amide-amide hydrogen bonds" <i>Chem. Commun.</i> , 1998, pp. 1067-1068.	
	R108	AAKERÖY, C. <i>et al.</i> "'Total synthesis' supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules" <i>Angew. Chem. Int. Ed.</i> , 2001, pp. 3240-3242, Vol. 40, No. 17.	
	R109	AAKERÖY, C. <i>et al.</i> "Two-fold interpenetration of 3-D nets assembled via three-co-ordinate silver(I) ions and amide-amide hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 1998, pp. 1943-1945.	
	R110	AHN, S. <i>et al.</i> "Polymorphs of a 1:1 cocrystal with tunnel and layer structures: <i>p,p'</i> -biphenol/dimethyl sulfoxide" <i>Crystal Growth & Design</i> , 2001, pp. 107-111, Vol. 1, No. 2.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
				Attorney Docket Number	TPI-350C1
Sheet	19	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R111	AKAZOME, M. <i>et al.</i> "Enantioselective inclusion of methyl phenyl sulfoxides and benzyl methyl sulfoxides by (R)-phenylglycyl-(R)-phenylglycine and the crystal structures of the inclusion cavities" <i>J. Org. Chem.</i> , 2000, pp. 68-76, Vol. 65.	
	R112	AKHTARUZZAMAN, M.D. <i>et al.</i> "One-dimensional hydrogen-bonded molecular tapes in 1, 4-bis[(4-pyridinio) ethynyl]benzene chloranilate" <i>Acta. Cryst.</i> , 2001, pp. o353-o355, Vol. E57.	
	R113	ALLEN, F. <i>et al.</i> "Systematic analysis of structural data as a research technique in organic chemistry" <i>Acc. Chem. Res.</i> , 1983, pp. 146-153, Vol. 16.	
	R114	ALMARSSON, Ö. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?" <i>Chem. Commun.</i> , 2004, pp. 1889-1896.	
	R115	AMAI, M. <i>et al.</i> "1:1 complex of octadecanoic acid and 3-pyridinecarboxamide" <i>Acta Cryst.</i> , 1998, pp. 1367-1369, Vol. C54.	
	R116	ANDERSON, N. <i>et al.</i> "Sulfonation with inversion by mitsunobu reaction: an improvement on the original conditions" <i>J. Org. Chem.</i> , 1996, pp. 7955-7958, Vol. 61.	
	R117	AOKI, K. <i>et al.</i> "A 1:1 complex of theophylline and <i>p</i> -nitrophenol" <i>Acta Cryst.</i> , 1978, pp. 2333-2336, Vol. B34.	
	R118	ASHTON, P. <i>et al.</i> "Combining different hydrogen-bonding motifs to self-assemble interwoven superstructures" <i>Chem. Eur. J.</i> , 1998, pp. 577-589, Vol. 4, No. 4.	
	R119	BARKER, P. A. <i>et al.</i> "Effect of crystallization temperature on the cocrystallization temperature on the cocrystallization of hydroxybutyrate/ hydroxyvalerate copolymers" <i>Polymer</i> , pp. 913-919, Vol. 38, No. 4.	
	R120	BERKOVITCH-YELLIN, Z. <i>et al.</i> "Electron density distribution in cumulenes: an x-ray study of the complex allenedicarboxylic acid- acetamide (1:1) at -150°C" <i>Acta Cryst.</i> , 1977, pp. 3670-3677, Vol. B33.	
	R121	BERKOVITCH-YELLIN, Z. <i>et al.</i> "The role played by C-H...O and C-H...N interactions in determining molecular packing and conformation" <i>Acta Cryst.</i> , 1984, pp. 159-165, Vol. B40.	
	R122	BERL, V. <i>et al.</i> "Induced fit selection of a barbiturate receptor from a dynamic structural and conformational/configurational library" <i>Eur. J. Org. Chem.</i> , 1999, pp. 3089-3094.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/660,202
			Filing Date	September 11, 2003
			First Named Inventor	Örn Almarsson
			Group Art Unit	1617
			Examiner Name	Leonard Williams
			Attorney Docket Number	TPI-350C1
Sheet	20	of	36	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R123	BERTOLASI, V. <i>et al.</i> "Competition between hydrogen bonding and donor-acceptor interactions in co-crystals of 1,3-dimethylbarbituric acid with aromatic amines" <i>New J. Chem.</i> , 2001, pp. 408-415, Vol. 25.	
	R124	BERTOLASI, V. <i>et al.</i> "General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals" <i>Acta Cryst.</i> , 2001, pp. 591-598, Vol. B57.	
	R125	BETTINETTI, G. <i>et al.</i> "Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex" <i>Journal of Pharmaceutical Sciences</i> , April 2000, pp. 478-489, Vol. 89, No. 4.	
	R126	BETTINETTI, G. <i>et al.</i> "Thermal analysis of binary systems of the pharmaceuticals trimethoprim and benzoic acid" <i>Journal of Thermal Analysis</i> , 1983, pp. 285-294, Vol. 28.	
	R127	BETTIS, J. <i>et al.</i> "Biopharmaceutics and dosage form design" <i>Amer. J. Hosp. Pharm.</i> , March 1973, pp. 240-243, Vol. 30.	
	R128	BOLTON, S. <i>et al.</i> "Complexes formed in solution by homologs of caffeine" <i>Journal of the American Pharmaceutical Association</i> , January 1957, pp. 38-41, Vol. XLVI, No. 1.	
	R129	BOND, A. "In situ co-crystallisation as a tool for low-temperature crystal engineering" <i>Chem. Commun.</i> , 2003, pp. 250-251, Vol. 2.	
	R130	BONIN, M. <i>et al.</i> "Urotropin azelate: a rather unwilling co-crystal" <i>Acta Cryst.</i> , 2003, pp. 72-86, Vol. B59.	
	R131	BOSSHARD, C. <i>et al.</i> "Microscopic nonlinearities of two-component organic crystals" <i>J. Opt. Soc. Am. B</i> , November 2001, pp. 1620-1626, Vol. 18, No. 11.	
	R132	GLUZMAN, M. Kh. <i>et al.</i> "Investigation of Eutectic Melting in Systems Composed of Organic Salts and Acids" <i>Journal of Physical Chemistry</i> , 1960, pp. 2742-2747, Vol. 34.	
	R133	BRAGA, D. <i>et al.</i> "Hydrogen bonding interactions between ions: a powerful tool in molecular crystal engineering" <i>Structure and Bonding</i> , 2004, pp. 1-32, Vol. 111.	
	R134	BRIERLEY, C. <i>et al.</i> "Preparation and structure of the 1:2 π -molecular complex of phenothiazine with pyromellitic dianhydride" <i>J. Chem. Phys.</i> , February 1, 1985, pp. 1522-1528, Vol. 82, No. 1.	
Examiner Signature	/Renee Claytor/		Date Considered
			11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	21	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R135	BURGI, H. <i>et al.</i> "Crystallisation of supramolecular materials" <i>Current Opinion in Solid State & Materials Science</i> , 1998, pp. 425-430, Vol. 3.	
	R136	BYRN, S. R. <i>et al.</i> "Solid-state pharmaceutical chemistry" <i>Chem. Mater.</i> , 1994, pp. 1148-1158, Vol. 6.	
	R137	CAIRA, M. "Molecular complexes of sulfonamides. Part 1. 1:1 complexes between sulfadimidine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl) benzenesulfonamide] and 2- and 4-aminobenzoic acids" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, pp. 641-648, Vol. 21, No. 5.	
	R138	CAIRA, M. "Molecular complexes of sulfonamides. Part 2. 1:1 complexes between drug molecules: sulfadimidine -acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1992, pp. 193-200, Vol. 22, No. 2.	
	R139	CAIRA, M. "Molecular complexes of sulfonamides. 3. Structure of 5-methoxysulfadiazine (Form II) and its 1:1 complex with acetylsalicylic acid" <i>Journal of Chemical Crystallography</i> , 1994, pp. 695-701, Vol. 24, No. 10.	
	R140	CAIRA, M. <i>et al.</i> "Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: crystallographic and thermal studies" <i>Journal of Pharmaceutical Sciences</i> , November 2003, pp. 2164-2176, Vol. 92, No. 11.	
	R141	CAIRA, M. <i>et al.</i> "Selective formation of hydrogen bonded cocrystals between a sulfonamide and aromatic carboxylic acids in the solid state" <i>J. Chem. Soc. Perkin Trans. 2</i> , 1995, pp. 2213-2216.	
	R142	CAIRA, M. <i>et al.</i> "Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid" <i>Journal of Chemical Crystallography</i> , 1998, Vol. 28, No. 1.	
	R143	CAMERMAN, A. <i>et al.</i> "Hydrogen bonding interaction of diphenylbarbituric acid and 9-ethyladenine. Crystal structure of a 1:1 complex" <i>Can. J. Chem.</i> , 2000, pp. 1045-1051, Vol. 78.	
	R144	CAMERMAN, A. <i>et al.</i> "Molecular structure of acetylacetone. A crystallographic determination" <i>J. Am. Chem. Soc.</i> , 1983, pp. 1584-1586, Vol. 105, No. 6.	
	R145	CANNON, A. <i>et al.</i> "Noncovalent derivatization: green chemistry applications of crystal engineering" <i>Crystal Growth & Design</i> , 2002, pp. 255-257, Vol. 2, No. 4.	
Examiner Signature	/Renee Claytor/		Date Considered
			11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	22	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R146	CHINNAKALI, K. <i>et al.</i> "2-aminopyrimidine and <i>p</i> -phenylene-diacetic acid (1:1) co-crystal" <i>Acta Cryst.</i> , 1999, pp. 399-401, Vol. C55.		
	R147	CHOI, C. <i>et al.</i> "Cocrystallization of melaminium levulinate monohydrate" <i>Acta Cryst.</i> , 2004, pp. o295-o296, Vol. C60.		
	R148	CHOW, Y. P. <i>et al.</i> "Complexation of acetaminophen with methyl xanthines" <i>Journal of Pharmaceutical Sciences</i> , 1972, pp. 1454-1458, Vol. 61.		
	R149	CHRISTIAN, S. <i>et al.</i> "Activity coefficient effects in spectral and solubility studies of molecular complex equilibria" <i>Journal of the American Chemical Society</i> , September 20, 1972, pp. 6861-6862, Vol. 94, No. 19, Communications to the editor.		
	R150	COLL, M. <i>et al.</i> "Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222, crystal form" <i>Journal of Biomolecular Structure & Dynamics</i> , 1990, pp. 315-330, Vol. 8, No. 2.		
	R151	COPP, S. <i>et al.</i> "Supramolecular chemistry of [Mn(CO) ₃ (μ ₃ -OH)] ₄ : Assembly of a cubic hydrogen-bonded diamondoid network with 1,2-diamineethane" <i>J. Am. Chem. Soc.</i> , 1992, pp. 8719-8720, Vol. 114.		
	R152	CORDI, A. <i>et al.</i> "(S)-Spiro [(1, 3-diazacyclopent-1-ene)-5, 2' -(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial α-adrenergic agonist" <i>J. Med. Chem.</i> , 1997, pp. 2931-2935, Vol. 40.		
	R153	CRAVEN, M. <i>et al.</i> "The 2:1 crystal complex of 5, 5-diethylbarbituric acid (barbital) and caffeine" <i>Acta Cryst.</i> , 1974, pp. 1191-1195, Vol. B30.		
	R154	CRAVEN, M. <i>et al.</i> "The crystal structures of two polymorphs of 5,5'-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1969, pp. 1978-1993, Vol. B25.		
	R155	CUDNEY, B. <i>et al.</i> "Screening and optimization strategies for macromolecular crystal growth" <i>Acta Cryst.</i> , 1994, pp. 414-423, Vol. D50.		
Examiner Signature	/Renee Claytor/		Date Considered	11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 23 of 36

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Group Art Unit	1617
Examiner Name	Leonard Williams
Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R156	DATTA, S. <i>et al.</i> "Molecular complex formation between riboflavin and salicylate in an aqueous medium" <i>Bull. Chem. Soc. Jpn.</i> , 2003, pp. 1729-1734, Vol. 76.	
	R157	DAVEY, R. J. <i>et al.</i> "Crystal engineering- nucleation, the key step" <i>Cryst. Eng. Comm.</i> , 2002, pp. 257-264, Vol. 4, No. 47.	
	R158	DAVEY, R. J. <i>et al.</i> "Crystallisation in polymer films: control of morphology and kinetics of an organic dye in a polysilicone matrix" <i>J. Mater. Chem.</i> , 1997, pp. 237-241, Vol. 7, No. 2.	
	R159	DEBERNARDIS, J. <i>et al.</i> "Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl) imidazoline: a potent agonist at α -adrenoceptors" <i>J. Med. Chem.</i> , 1987, pp. 1011-1017, Vol. 30.	
	R160	DESIRAJU, G. <i>et al.</i> "Crystal and co-crystal" <i>Cryst. Eng. Comm.</i> , 2003, pp. 466-467, Vol. 5, No. 82.	
	R161	DESIRAJU, G. <i>et al.</i> "Crystal engineering: outlook and prospects" <i>Current Science</i> , October 25, 2001, pp. 1038-1042, Vol. 81, No. 8.	
	R162	DUAX, W. <i>et al.</i> "The structure of the crystalline complex estradiol. Urea (1:1)" <i>Acta Cryst.</i> , 1972, pp. 1864-1871, Vol. B28.	
	R163	DUNITZ, J. "Crystal and co-crystal: a second opinion" <i>Cryst. Eng. Comm.</i> , 2003, pp. 506, Vol. 5, No. 91.	
	R164	DUNITZ, J. "New light on an old story: the solid-state transformation on ammonium cyanate into urea" <i>J. Am. Chem. Soc.</i> , 1998, pp. 13274-13275, Vol. 120.	
	R165	ENRIGHT, G. <i>et al.</i> "Thermally programmable gas storage and release in single crystals of an organic van der Waals host" <i>J. Am. Chem. Soc.</i> , 2003, pp. 9896-9897, Vol. 125.	
	R166	EPSTEIN, R. <i>et al.</i> "The x-ray crystal structure of the molecular complex 8-bromo-9-ethyladenine-5-allyl-5-isobutylbarbituric acid" <i>Acta Cryst.</i> , 1976, pp. 2180-2188, Vol. B32.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	24	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R167	ETTER, M. "Encoding and decoding hydrogen-bond patterns of organic compounds" <i>Acc. Chem. Res.</i> , 1990, pp. 120-126, Vol. 23.	
	R168	ETTER, M. <i>et al.</i> "Graph-set analysis of hydrogen-bond patterns in organic crystals" <i>Acta Cryst.</i> , 1990, pp. 256-262, Vol. B46.	
	R169	ETTER, M. <i>et al.</i> "Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides" <i>J. Am. Chem. Soc.</i> , 1991, pp. 2586-2598, Vol. 113.	
	R170	ETTER, M. "Hydrogen bonds as design elements in organic chemistry" <i>J. Phys. Chem.</i> , 1991, pp. 4601-4610, Vol. 95.	
	R171	FABIAN, L. <i>et al.</i> "Volumetric measure of isostructurality" <i>Acta Cryst.</i> , 1999, pp. 1099-1108, Vol. B55.	
	R172	FALLON III, L. "The crystal and molecular structure of 5-fluorouracil" <i>Acta Cryst.</i> , pp. 2549-2556, Vol. B29. ¹⁹⁷³	
	R173	FEIBUSH, B. <i>et al.</i> "Chiral separation of heterocyclic drugs by HPLC: solute-stationary phase base-pair interactions" <i>J. Am. Chem. Soc.</i> , 1986, pp. 3310-3318, Vol. 108.	
	R174	FIFER, E. <i>et al.</i> "Fentanyl analogues 3. 2-(1,2,3,4-tetrahydro)-naphthyl substituted 4-anilidopiperidines" <i>Eur. J. Med. Chem.-Chim. Ther.</i> , 1984, pp. 519-524, Vol. 19, No. 6.	
	R175	RECK, G. <i>et al.</i> "Crystal structures of the carbamazepine/ammonium chloride and carbamazepine/ammonium bromide adducts and their transformation into carbamazepine dihydrate" <i>Pharmazie</i> , 1991, pp. 509-512, Vol. 46, No. 7.	X
	R176	FOXMAN, B. M. <i>et al.</i> "Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquinones" <i>Crystal Engineering</i> , 1998, pp. 109-118, Vol. 1, No. 1.	
	R177	FOXMAN, B. M. <i>et al.</i> "Noncovalent derivatives of hydroquinone: BIS- (N,N-dialkyl) bicyclo[2.2.2]octane-1,4-dicarboxamide complexes" <i>Crystal Engineering</i> , 1999, pp. 55-64, Vol. 2, No. 1.	
	R178	FUJII, S. <i>et al.</i> "Crystal and molecular structure of a 1:1 molecular complex of adenine and riboflavin" <i>Archives of Biochemistry and Biophysics</i> , 1977, pp. 363-370, Vol. 181.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	25	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R179	GAO, X. <i>et al.</i> "Supramolecular construction of molecular ladders in the solid state" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 232-236, Vol. 43.	
	R180	GARTLAND, G. L. <i>et al.</i> "Hydrogen bonding NH...O=C of barbiturates: the (1:1) crystal complex of urea and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 980-987, Vol. B30.	
	R181	GHOSH, M. "Structure and conformation of the 1:1 molecular complex sulfaproxyline-caffeine" <i>Acta Cryst.</i> , 1991, pp. 577-580, Vol. C47.	
	R182	GIUSEPPE, G. P. <i>et al.</i> "The crystal structure of a sulfamethoxazole-trimethoprim 1:1 molecular compound" <i>Il Farmaco- Ed. Sc.</i> , pp. 138-151, Vol. 35. 1980	
	R183	GOSWAMI, S. <i>et al.</i> "2-aminopyrimidine-fumaric acid cocrystal" <i>Acta Cryst.</i> , 1999, pp. 583-585, Vol. C55.	
	R184	HAYNES, D. "Supramolecular synthon competition in organic sulfonates: A CSD survey" <i>Cryst. Eng. Comm.</i> , 2004, pp. 584-588, Vol. 6, No. 95.	
	R185	GOSWAMI, S. <i>et al.</i> "1:1 Hetero-assembly of 2-amino-pyrimidine and (+)-camphoric acid" <i>Acta Cryst.</i> , 2000, pp. 477-478, Vol. C56.	
	R186	GOSWAMI, S. <i>et al.</i> "Molecular recognition induced supramolecular array of 2-aminopyrimidine with terephthalic acid, 1,4-phenylenediacetic acid and fumaric acid in solid state via H-bonding and π -stacking interactions" <i>Supramolecular Chemistry</i> , 1999, pp. 25-33, Vol. 11.	
	R187	GRAJA, A. <i>et al.</i> "Interplay of acceptor molecule shape, crystal structure and physical properties of a new molecular complex $C_{70} \cdot 2[(Ph_3P) AuCl]$ " <i>Chemical Physics Letters</i> , November 19, 1999, pp. 725-732. Vol. 313.	
	R188	HAIXIN, L. <i>et al.</i> "Structure of the 1:1 complex of 6,6'-diquinolyl ether with 5,5-diethylbarbituric acid" <i>Acta Cryst.</i> , 1992, pp. 2096-2098, Vol. C48.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	26	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R189	HENCK, J. <i>et al.</i> "Disappearing and reappearing polymorphs. The benzocaine:picric acid system" <i>J. Am. Chem. Soc.</i> , 2001, pp. 1834-1841, Vol. 123.	
	R190	HIGUCHI, T. <i>et al.</i> "Complexation of organic substances in aqueous solution by hydroxyaromatic acids and their salts" <i>J. Pharm. Sci.</i> , 1961, pp. 905-909, Vol. 50.	
	R191	HINO, T. <i>et al.</i> "Assessment of nicotinamide polymorphs by differential scanning calorimetry" <i>Thermochimica Acta</i> , 2001, pp. 85-92, Vol. 374.	
	R192	HÖGBERG, T. <i>et al.</i> "Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D ₂ antagonist" <i>J. Pharm. Pharmacol.</i> , 1987, pp. 787-796, Vol. 39.	
	R193	HSU, I. <i>et al.</i> "The 2:1 crystal complex of 2-aminopyridine and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 994-997, Vol. B30.	
	R194	HSU, I. <i>et al.</i> "The 1:1 crystal complex of N-methyl-2-pyridone and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 998-1001, Vol. B30.	
	R195	HSU, I. <i>et al.</i> "The crystalline complex (1:1) of salicylamide and 5-ethyl-5-isoamylbarbituric acid (amobarbital)" <i>Acta Cryst.</i> , 1974, pp. 843-846, Vol. B30.	
	R196	HSU, I. <i>et al.</i> "The crystal structure of the 1:1 complex of acetamide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 974-979, Vol. B30.	
	R197	HSU, I. <i>et al.</i> "The crystal structure of the triclinic 1:2 complex of hexamethylphosphoramide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 1299-1304, Vol. B30.	
	R198	HSU, I. <i>et al.</i> "Hydrogen bonding NH...N of barbiturates: The 1:1 crystal complex of imidazole and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 988-993, Vol. B30.	
	R199	IBRAGIMOV, B. "A simple correlation between the structures of different crystal modifications of a given host-guest complex and their crystallization temperatures" <i>Journal of Inclusion of Phenomena and Macrocyclic Chemistry</i> , 1999, pp. 345-353, Vol. 34.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	27	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R200	ISHIDA, T. <i>et al.</i> "Structural study of histamine H ₂ -receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolymethylthio] propionamidine and -amide derivatives" <i>Acta Cryst.</i> , 1989, pp. 505-512, Vol. B45.	
	R201	KATAKAI, R. <i>et al.</i> "Stepwise synthesis of oligopeptides with N-carboxy-α-amino acid anhydrides. IV. Glycine NCA" <i>J. Org. Chem.</i> , 1972, pp. 327-329, Vol. 37, No. 2.	
	R202	KAWAKAMI, Y. <i>et al.</i> "The rationale for E2020 as a potent acetylcholinesterase inhibitor" <i>Bioorganic & Medicinal Chemistry</i> , 1996, pp. 1429-1446, Vol. 4, No. 9.	
	R203	KELDERS, H. <i>et al.</i> "Automated protein crystallization and a new crystal form of a subtilisin: eglin complex" <i>Protein Engineering</i> , 1987, pp. 301-303, Vol. 1, No. 4.	
	R204	KHALIL, R. M. "Complexation of paracetamol with xanthine derivatives" <i>Egypt. J. Pharm. Sci.</i> , 1992, pp. 757-769, Vol. 33, No. 5-6.	
	R205	KIM, S. "Crystal structure of the 1:1 complex of 5-fluorouracil and 9-ethylhypoxanthine" <i>Science</i> , November 24, 1967, pp. 1046-1048, Vol. 158, No. 3804.	
	R206	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-barbital complex" <i>Journal of Pharmaceutical Sciences</i> , May 1971, pp. 699-703, Vol. 60, No. 5.	
	R207	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-cyclobarbitol complex" <i>Chem. Pharm. Bull.</i> , 1974, pp. 1588-1592, Vol. 22.	
	R208	KLEIN, C. <i>et al.</i> "Molecular structure of two conformationally restrained fentanyl analogues: cis- and trans-isomers of N-[3-methyl-1-[1,2,3,4-tetrahydro) naphthyl]-4-piperidinyl]-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R209	KOSHIMA, H. <i>et al.</i> "Photoreactivities of two kinds of bimolecular crystals formed from acridine and phenothiazine" <i>J. Chem. Soc., Perkins Trans. 2</i> , 1997, pp. 2033-2038.	
	R210	KOSHIMA, H. <i>et al.</i> "Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid" <i>Crystal Growth & Design</i> , 2001, pp. 355-357, Vol. 1, No. 5.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	28	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R211	KRISHNAMOHAN SHARMA, C. V. <i>et al.</i> "X-ray crystal structure of C ₆ H ₃ (CO ₂ H) ₃ -1,3,5-1.5(4,4'-bipy): a 'super trimesic acid' chicken-wire grid" <i>Chem. Commun.</i> , 1996, pp. 2655-2656.	
	R212	KURODA, R. <i>et al.</i> "Generation of a co-crystal phase with coloristic properties via solid state grinding procedures" <i>Chem. Commun.</i> , 2002, pp. 2848-2849.	
	R213	LEISEROWITZ, L. <i>et al.</i> "The molecular packing modes and hydrogen-bonding properties of amide: dicarboxylic acid complexes" <i>Acta Cryst.</i> , 1977, pp. 2719-2733, Vol. B33.	
	R214	LEISEROWITZ, L. "Molecular packing modes. Carboxylic acids" <i>Acta Cryst.</i> , 1976, pp. 775-802, Vol. B32.	
	R215	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXXI adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids" <i>Aust. J. Chem.</i> , 1998, pp. 403-408, Vol. 51.	
	R216	MACGILLIVRAY, L. <i>et al.</i> "Supramolecular control of reactivity in the solid state using linear molecular templates" <i>J. Am. Chem. Soc.</i> , 2000, pp. 7817-7818, Vol. 122.	
	R217	MATHIAS, J. <i>et al.</i> "Structural preferences of hydrogen-bonded networks in organic solution- the cyclic CA ₃ •M ₃ 'rosette'" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4316-4325, Vol. 116.	
	R218	MASTROPAOLO, D. <i>et al.</i> "Hydrogen bonding interaction of diphenylhydantoin and 9-ethyladenine" <i>Molecular Pharmacology</i> , 1983, pp. 273-277, Vol. 23.	
	R219	MARYANOFF, B. "Stereochemistry in a medium-sized ring. Highly diastereoselective N-oxidation of a substituted 3-benzazonine. X-ray crystal structure of an unusual complex between an amine N-oxide and saccharin" <i>J. Org. Chem.</i> , 1990, pp. 760-764, Vol. 55.	
	R220	MARTIN, R. <i>et al.</i> "The caffeine-potassium chlorogenate molecular complex" <i>Phytochemistry</i> , 1987, pp. 273-279, Vol. 26, No. 1.	
	R221	ANDERSON, J. "Constitution of aurous compounds: Gold mirrors" <i>Nature</i> , October 2, 1937, pp. 583-584, Letters to the Editor.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	29	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R222	ROBBINS, A. H. <i>et al.</i> "The crystal structure of the 1:2 adduct of potassium triiodide and 5,5-diethylbarbituric acid (barbital)" <i>American Crystallographic Association- Series 2, Papers and Abstracts</i> , 1973, p. 87.	
	R223	BEERGES, P. <i>et al.</i> "Phenothiazine tetracyanoethylene" <i>Private Communication</i> , 1994.	
	R224	MADARASZ, J. <i>et al.</i> "Thermal, ftir and xrd study on some 1:1 molecular compounds of theophylline" <i>Journal of Thermal Analysis and Calorimetry</i> , 2002, pp. 281-290, Vol. 69.	
	R225	CARONNA, T. <i>et al.</i> "Halogen bonding and $\pi \cdots \pi$ stacking control reactivity in the solid state" <i>J. Am. Chem. Soc.</i> , 2004, pp. 4500-4501, Vol. 126.	
	R226	ZERKOWSKI, J. <i>et al.</i> "Steric control of secondary, solid-state architecture in 1:1 complexes of melamines and barbiturates that crystallize as crinkled tapes" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4298-4304, Vol. 116.	
	R227	ZAITU, S. <i>et al.</i> "1:1 Molecular complex of theophylline and <i>p</i> -nitroaniline" <i>Acta Cryst.</i> , 1995, pp. 2390-2392, Vol. C51.	
	R228	KOFLER, L. <i>et al.</i> , <u>Thermal micromethods for the study of organic compounds and their mixtures</u> , pp. 1-145, 148-351, 354-386, Innsbruck, Austria, 1980.	
	R229	QUEHENBERGER, H. "Concerning organic molecular compounds and their polymorphism" <i>Monatshefte für Chemie</i> , 1949, pp. 595-606, Vol. 80, No. 5.	X
	R230	WIEDENFELD, H. <i>et al.</i> "The crystal structure of the theophylline-urea complex" <i>Arch. Pharm.</i> , 1986, pp. 654-659, Vol. 319.	X
	R231	BUNICK, G. <i>et al.</i> "The crystal and molecular structure of the complex 2,6-diamino-9-ethylpurine 5,5-diethylbarbituric acid" <i>American Crystallographic Association, Abstract Papers</i> Winter 1976, p. 30.	
	R232	BUCZAK, G. <i>et al.</i> "Crystal structure and vibrational spectra of the 1:1 and 1:2 complexes of pyridine betaine with pentachlorophenol" <i>Journal of Molecular Structure</i> , 1997, pp. 143-151, Vol. 436-437.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	23	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R233	TOMURA, M. <i>et al.</i> "One-dimensional zigzag chain structures with intermolecular C-H... π and C-H...O interactions consisted of phthalic acid and pyridine derivatives" <i>Chemistry Letters</i> , 2001, pp. 532-533.	
	R234	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid-melamine complex" <i>J. Am. Chem. Soc.</i> , 1994, pp. 2382-2391, Vol. 116.	
	R235	HARKEMA, S. <i>et al.</i> "The crystal structure of urea oxalic acid (2:1)" <i>Acta Cryst.</i> , 1972, pp. 1646-1648, Vol. B28.	
	R236	KRANTZ, J. <i>et al.</i> "Sodium theophylline glycinate" <i>Journal of the American Pharmaceutical Association</i> , 1946, pp. 248-250.	
	R237	DATTA, S. <i>et al.</i> "Crystal structures of drugs: advances in determination, prediction and engineering" <i>Nature</i> , January 2004, pp. 42-57, Vol. 3.	
	R238	AAKERÖY, C. <i>et al.</i> "Charge-assisted hydrogen bonds and halogen-halogen interactions in organic salts: benzylammonium benzoates and pentafluorobenzoates" <i>Structural Chemistry</i> , 1999, pp. 229-242, Vol. 10, No. 3.	
	R239	CHILDS, S. <i>et al.</i> "Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids" <i>J. Am. Chem. Soc.</i> , 2004, pp. 13335-13342, Vol. 126.	
	R240	AAKERÖY, C. <i>et al.</i> "Modular supramolecular synthesis based on a dominance hierarchy of intermolecular interactions (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R241	HELFRICH, B. <i>et al.</i> "Polymorphism as an indication of structural versatility (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R242	WEBER, E. <i>et al.</i> "Synthesis of new Schiff bases: reaction of monofluorobenzaldehydes with 3-aminosulfonamide hydrochloride (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	

Examiner Signature	/Renee Clayton/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	31	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R243	SCARBROUGH, F. <i>et al.</i> "Crystal structure of a complex between lumiflavin and 2,6-diamino-9-ethylpurine: a flavin adenine dinucleotide model exhibiting charge-transfer interactions" <i>Proc. Natl. Acad. Sci. USA</i> , November 1976, pp. 3807-3811, Vol. 73, No. 11.	
	R244	MUNN, R. <i>et al.</i> "A Model for resonance-assisted hydrogen bonding in crystals and its graph set analysis" <i>J. Phys. Chem. A</i> , 2001, pp. 6938-6942, Vol. 105.	
	R245	LYNCH, D. <i>et al.</i> "1:1 Molecular complexes of 4-amino-N-(4,6-dimethylpyrimidin-2-yl) benzene-sulfonamide (sulfamethazine) with indole-2-carboxylic acid and 2,4-dinitrobenzoic acid" <i>Aust. J. Chem.</i> , 2000, pp. 383-387, Vol. 53.	
	R246	AAKEROY, C. <i>et al.</i> "Solid state, crystal engineering and hydrogen bonds" <i>Comprehensive Coordination Chemistry II</i> (ed. by McCleverty, J. <i>et al.</i>), pp. 679-688, Elsevier Ltd., Oxford, UK. 2004	
	R247	LEVIN, B. <i>et al.</i> "The not-so-trivial synthesis and characterization of heterocyclic boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R248	SMITH, G. <i>et al.</i> "Interactions of aromatic carboxylic acids with quinolin-8-ol (oxine): Synthesis and the crystal structures of the proton-transfer compounds with the nitro-substituted benzoic acids" <i>Aust. J. Chem.</i> , 2001, pp. 171-175, Vol. 54.	
	R249	STALKER, R. <i>et al.</i> "Asymmetric synthesis of two new conformationally constrained lysine derivatives" <i>Tetrahedron</i> , 2002, pp. 4837-4849, Vol. 58.	
	R250	VOET, D. <i>et al.</i> "Barbiturates and adenine derivatives. Molecular structure of a hydrogen-bonded complex" <i>Journal of the American Chemical Society</i> , August 9, 1972, pp. 5888-5891, Vol. 94, No. 16.	
	R251	VISHWESHWAR, P. <i>et al.</i> "Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation" <i>Crystal Growth & Design</i> , 2003, pp. 783-790, Vol. 3, No. 5.	
	R252	LE JEUNNE, C. <i>et al.</i> "Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks" <i>Eur. Neurol.</i> , 1999, pp. 37-43, Vol. 41.	
	R253	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonded layers of hydrogentartrate anions: two-dimensional building blocks for crystal engineering" <i>J. Mater. Chem.</i> , 1993, 1129-1135, Vol. 3, No. 11.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R254	HU, Z. <i>et al.</i> "Separation of 4-aminobenzoic acid by cocrystallization: Crystal structure of the complex of 4-aminobenzoic acid with (2R,3R)-tartaric acid" <i>Journal of Chemical Crystallography</i> , December 2002, pp. 525-529, Vol. 32, No. 12.	
	R255	GUARRERA, D. <i>et al.</i> "Molecular self-assembly in the solid state. The combined use of solid state NMR and differential scanning calorimetry for the determination of phase constitution" <i>Chem. Mater.</i> , 1994, pp. 1293-1296, Vol. 6.	
	R256	DOI, M. <i>et al.</i> "Conformational study of a potent human renin inhibitor: x-ray crystal structure of isopropyl (2R, 3S) -4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl) propionyl] -L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleavage site of angiotensinogen" <i>J. Chem. Soc. Perkin Trans. 1</i> , 1991, pp. 1153-1158.	
	R257	CRIHFELD, A. <i>et al.</i> "Crystal engineering through halogen bonding. 2. Complexes of diacetylene-linked heterocycles with organic iodides" <i>Crystal Growth & Design</i> , 2003, pp. 313-320, Vol. 3, No. 3.	
	R258	AAKERÖY, C. <i>et al.</i> "A versatile route to porous solids: organic-inorganic hybrid materials assembled through hydrogen bonds" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 1815-1819, Vol. 38, No. 12.	
	R259	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-theophylline complex.	
	R260	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-sulfanilamide complex.	
	R261	WIEDENFELD, H. <i>et al.</i> "Solubilization of aminophenazone" <i>Arch. Pharm.</i> , 1982, pp. 633-641, Vol. 315.	X
	R262	CACCIAPUOTI, A. <i>et al.</i> "In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against <i>Aspergillus</i> and <i>Candida</i> " <i>Antimicrobial Agents and Chemotherapy</i> , August 2000, pp. 2017-2022, Vol. 44, No. 8.	
	R263	CALLAHAN, J.C. <i>et al.</i> "Equilibrium moisture content of pharmaceutical excipients" <i>Drug Development and Industrial Pharmacy</i> , 1982, pp. 355-369, Vol. 8, No. 3.	
	R264	DANNAOUI, E. <i>et al.</i> "Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 2001, pp. 333-340, Vol. 47.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
				Attorney Docket Number	TPI-350C1
Sheet	33	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R265	DENNING, D. W. <i>et al.</i> "In vitro activity of Saperconazole (R66 905) compared with Amphotericin B and Itraconazole against <i>Aspergillus</i> species" <i>Eur. J. Clin. Microbial. Infect. Dis.</i> , 1990, pp. 693-697, Vol. 9.	
	R267	DRESSMAN, J. B. <i>et al.</i> "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms" <i>Pharmaceutical Research</i> , 1998, pp. 11-22, Vol. 15, No. 1.	
	R268	EBERT, W. R. "Soft elastic gelatin capsules: a unique dosage form" <i>Pharmaceutical Technology</i> , October 1977, pp. 44-50, Vol. 1, No. 5.	
	R269	GASCON, M. -P. <i>et al.</i> "In vitro forecasting of drugs which may interfere with the biotransformation of midazolam" <i>Eur. J. Clin. Pharmacol.</i> , 1991, pp. 573-578, Vol. 41.	
	R270	HEERES, J. <i>et al.</i> "Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones" <i>J. Med. Chem.</i> , 1984, pp. 894-900, Vol. 27.	
	R271	HONIG, P. K. <i>et al.</i> "Itraconazole affects single-dose Terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics" <i>J. Clin. Pharmacol.</i> , 1993, pp. 1201-1206, Vol. 33.	
	R272	IMAI, T. <i>et al.</i> "Successful treatment of cerebral Aspergillosis with a high oral dose of Itraconazole after excisional surgery" <i>Internal Medicine</i> , October 1999, pp. 829-832, Vol. 38, No. 10.	
	R273	KOVACS, J. <i>et al.</i> "New type of bridged monoamino- β -cyclodextrins" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1996, pp. 53-56, Vol. 25.	
	R274	LAVRIJSEN, A. P. M. <i>et al.</i> "Hepatic injury associated with itraconazole" <i>The Lancet</i> , July 25, 1992, pp. 251-252, Vol. 340.	
	R275	NEUVONEN, P. J. <i>et al.</i> "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" <i>Clinical Pharmacology & Therapeutics</i> , 1996, pp. 54-61, Vol. 60, No. 1.	
	R276	NOMEIR, A. A. <i>et al.</i> "Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys" <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, pp. 727-731, Vol. 44, No. 3.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	34	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R277	ODDS, F. C. "Antifungal activity of saperconazole (R 66 905) <i>in vitro</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 1989, pp. 533-537, Vol. 24.	
	R278	REMENAR, J. F. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	
	R279	SAKSENA, A. K. <i>et al.</i> "Advances in the chemistry of novel broad-spectrum orally active azole antifungals: recent studies leading to the discovery of SCH 56592" in <i>Advances in the Chemistry of Novel Broad-Spectrum Orally Active Azole Antifungals</i> (Royal Soc. Chem., Cambridge), 1997, pp. 180-199.	
	R280	SAKSENA, A. K. <i>et al.</i> "Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592" <i>Tetrahedron Letters</i> , 1996, pp. 5657-5660, Vol. 37, No. 32.	
	R281	HEPPERLE, M. <i>et al.</i> "Mono <i>N</i> -arylation of piperazine(III): metal-catalyzed <i>N</i> -arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate" <i>Tetrahedron Letters</i> , 2002, pp. 3359-3363, Vol. 43.	
	R282	CUTSEM, J. V. <i>et al.</i> "Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals" <i>Antimicrobial Agents and Chemotherapy</i> , December 1989, pp. 2063-2068, Vol. 33, No. 12.	
	R283	VILLA, L. A. <i>et al.</i> "Central nervous system paracoccidioidomycosis. Report of a case successfully treated with itraconazole" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August, 2000, pp. 231-234, Vol. 42, No. 4.	
	R284	WEST, A. R., "Solid Solutions" In: <i>Solid State Chemistry and its Applications</i> , 1988, p. 358, p. 365, Wiley, NY.	
	R285	ARONHIME, J. <i>et al.</i> "Crystalline forms of pharmaceuticals and characterization thereof", Oral Presentation, March 8, 2005, USPTO, Alexandria, VA.	
	R286	DESIRAJU, G. R. "Chemistry beyond the molecule" <i>Nature</i> , July 26, 2001, pp. 397-400, Vol. 412.	
	R287	GAVEZZOTTI, A. "Are crystal structures predictable?" <i>Acc. Chem. Res.</i> , 1994, pp. 309-314, Vol. 27.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Leonard Williams	
			Attorney Docket Number	TPI-350C1	
Sheet	35	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R288	Physician's Desk Reference, 56 th Ed., pp. 1800-1804, 2002.	
	R289	KIM, H. <i>et al.</i> "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum" <i>Journal of Chromatography B</i> , 2000, pp. 93-98, Vol. 738.	
	R290	VIPPAGUNTA, S. R. <i>et al.</i> "Crystalline solids" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 3-26, Vol. 48.	
	R291	MCCRONE, W. C. "Polymorphism", In: <i>The Physics and Chemistry of the Organic Solid State</i> , Vol. II, FOX, D. <i>et al.</i> (eds.), 1965, pp. 725-767, Interscience, New York.	
	R292	LEGER, J.M. <i>et al.</i> "Crystal Structure of the 1:1 Sulfacetamide-Caffeine Complex" <i>Acta Cryst.</i> , 1977, pp. 1455-1459, Vol. B33.	X
	R293	SIMONOV, Y. <i>et al.</i> "Structure of the caffeine-copper(II) acetate additional compound", <i>Izvestiya Akademii Nauk Moldavskoi SSR, Seriya Fiziko-Tekhnicheskikh i Matematicheskikh Nauk</i> , 1972, Vol. 3, pp. 83-84, abstract only.	
	R294	WEISSBUCH, I. <i>et al.</i> "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" <i>Acta Cryst.</i> , 1995, B51:115-148.	
	R295	FAUGHT, E. <i>et al.</i> "Topiramate Dose-Ranging Trial in Refractory Partial Epilepsy", <i>Amer. Epilepsy Soc. Proc.</i> , (1995), pg. 33, Vol. 36, Supp. 4.	
	R296	PRIVITERA, M. <i>et al.</i> "Dose-Ranging Trial with Higher Doses of Topiramate in Patients with Resistant Partial Seizures", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R297	SACHDEO, S. K. <i>et al.</i> "Topiramate: Double-Blind Trial as Monotherapy", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R298	Press Release. "Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability". http://www.orthomcneil.com/news/article020402.html (February 4, 2002), N.J.	X

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	36	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R299	ROSENFELD, W. E. "Topiramate: A Review of Preclinical, Pharmacokinetic, and Clinical Data", <i>Clinical Therapeutics</i> , 1997, pp. 1294-1308, Vol. 19, No. 6.	
	R300	Physician's Desk Reference, 56 th Edition, 2002, pp. 2590-2595.	
	R301	DATABASE WPI, Section Ch, Week 197936, Derwent Publishing Ltd., London, Great Britain, Class B02, AN 1979-65538B, XP002282989 and JP 54 095589A (Sumitomo) 1979 Abstract.	
	R302	FUNG <i>et al.</i> , "Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates," <i>Chem. Farm. Bull.</i> , 22(2), pgs. 454-458 (1974).	
	R303	RUBINO <i>et al.</i> , "Influence of Solvent Composition on the Solubilities and Solid-State Properties of the Sodium Salts of Some Drugs", <i>Int. J. of Pharma</i> , 65, pgs. 141-145 (1990).	
	R304	FITZGERALD, G. A. "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", <i>New England Journal of Medicine</i> , Vol. 345, No. 6, August 9, 2001.	
	R305		
	R306		
	R307		
	R308		
	R309		

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/